株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の抗肥満薬市場:2011〜2021年

World Anti-Obesity Drug Market 2011-2021

発行 Visiongain Ltd 商品コード 178609
出版日 ページ情報 英文 209 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=146.92円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界の抗肥満薬市場:2011〜2021年 World Anti-Obesity Drug Market 2011-2021
出版日: 2011年02月21日 ページ情報: 英文 209 Pages
概要

当レポートでは、世界における肥満症の治療薬市場の収益予測と成長率、市場シェア、SWOT分析、研究開発動向などをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 抗肥満薬市場のイントロダクション

  • 肥満とは
  • 肥満につながる因子
  • 肥満測定
  • 肥満は社会経済的負担が大きい
  • 肥満は多くの国で課題となっている
  • 現在の治療法
  • 抗肥満薬:作用機序

第3章 世界の抗肥満薬市場:2011〜2021年

  • 2009年以降の抗肥満薬売上:市場概要
  • 主要企業と製品
  • 現在の課題
  • 世界の抗肥満薬市場全体の予測:2011〜2021年

第4章 治療クラス別抗肥満薬予測:2011〜2021年

  • リパーゼ阻害剤
  • 食欲減退薬
  • フェンテルミン
  • その他:世界市場予測
  • 市場サマリー

第5章 世界の抗肥満薬市場の促進因子と阻害因子:2011〜2021年

第6章 肥満治療の研究開発

  • 現在第3相にある治療薬
  • 現在第2相にある治療薬
  • 現在第1層にある治療薬
  • 有望パイプライン

第7章 主要国市場

第8章 専門家の見解

第9章 結論

  • 肥満は健康に重大な影響を及ぼす慢性疾患
  • 抗肥満薬市場は2011〜2021年に拡大
  • 抗肥満薬市場の主な促進因子と阻害因子
  • 抗肥満薬市場の地域的概要
  • 将来見通し

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

- what will the future hold for obesity-treatment drugs?

What will this decade hold for the challenged anti-obesity drug industry and market? Our new report gives you revenue forecasts at world, product and national level.

We provide original research, data and opinions to benefit your work. By ordering now, you can stay ahead. We aim to save you time and benefit your decisions.

How will the regulatory and marketing difficulties facing anti-obesity drugs affect companies and their revenues? In our report you will see prospects for obesity drug research, development, launches and marketing from 2011 onwards.

We predict the overall world market and leading national markets. The increasing prevalence of obesity has created pharma market opportunities in many countries.

Where will the best revenue prospects in obesity treatment lie from 2011 to 2021? Our study provides the answers you need for that pharma market.

Although sales have been modest so far, weight-loss drugs can gain acceptance from more prescribers, patients and payers. The prescription drug market for obesity can grow, despite setbacks at present, our study shows. You will see how.

Anti-obesity drugs with improved clinical effectiveness, safety and ease of use can gain therapeutic and commercial success, our report explains. We show R&D progress there.

You will see strengths, weaknesses and revenue prospects of the anti-obesity drug market from 2009 to 2021. We show what companies are doing, and how competition is shaping up in that challenging environment.

In our report you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Respond now to get that information.

Analysis and expert opinion to help your work - so you won' t be left behind

Our new report gives you revenue forecasts, growth rates, market shares, SWOT analysis, an R&D review and expert opinion. We include 78 tables and charts and two interviews (shown in the accompanying lists).

World Anti-Obesity Drug Market 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

  • You will receive hard data for the anti-obesity drug industry and market - especially our revenue forecasts to 2021
  • You will discover revenues for the overall market and its main products from 2009 to 2021 - seeing where commercial growth will occur
  • You will find revenue forecasts for leading products from 2011 to 2021, with discussions of market potential and competition
  • You will find revenue forecasts for leading national markets from 2011 to 2021 (US, UK, Germany, France, Spain, Italy, Russia and India)
  • You will learn how the anti-obesity drug industry can change and adapt from 2011 to 2021
  • You will assess leading companies in obesity treatments, discovering their activities and outlook
  • You will see what will stimulate and restrain the industry and market from 2011 onwards
  • You will identify R&D pipeline advances and up-and-coming products
  • You will investigate commercial requirements - with therapeutic needs and market opportunities discussed
  • You will view expert opinion from our survey, including full interview transcripts
  • You will find out where the industry and market are heading - technology, competition and revenues.

That mix of quantitative and qualitative market analysis sets our report apart. Our emphasis is on future revenue trends. We give you market predictions found only in our work. Our independent analysis can help you stay ahead of your competitors.

You can order our report, receiving the market information you need

Our report can benefit everybody interested in anti-obesity drug development, production, marketing and sales. You will find answers and predictions you need. Please order our report now, making sure you don' t miss out.

Table of Contents

1. Executive Summary

  • 1.1. The Anti-Obesity Drug Market Has Potential to Increase its Revenues
  • 1.2. Aims, Scope and Format of the Report
  • 1.3. Research and Analysis Methods

2. Introduction to the Anti-Obesity Drug Market

  • 2.1. What is Obesity?
    • 2.1.1. Obesity as a Chronic Disorder
    • 2.1.2. Obesity in Children
  • 2.2. Factors Leading to Obesity
    • 2.2.1. Genetic Factors
    • 2.2.2. Psychological Factors
    • 2.2.3. Environmental, Behavioural and Social Factors
    • 2.2.4. Drug Factors
    • 2.2.5. Mental and Physical Disability Factors
    • 2.2.6. Other Factors
    • 2.2.7. Antecedent Illnesses and Treatments
  • 2.3. Measurement of Obesity
    • 2.3.1. How is Obesity Measured?
    • 2.3.2. Weight-for-Height Tables
    • 2.3.3. Waist Circumference
    • 2.3.4. Body Mass Index (BMI)
  • 2.4. Obesity Has High Socio-Economic Costs
    • 2.4.1. Consequences of Obesity: Co-Morbidities Linked to Obesity
  • 2.5. Obesity is a Rising Challenge in Many Countries
    • 2.5.1. Obesity in Established Markets
    • 2.5.2. Current Burden of Obesity in Emerging Markets
  • 2.6. Current Treatments for Obesity
    • 2.6.1. Lifestyle and Dietary Changes
    • 2.6.2. Unapproved Drugs in the Market
    • 2.6.3. Alternative Therapies
    • 2.6.4. Use of Drugs to Treat Obesity
    • 2.6.5. Surgical Options
  • 2.7. Anti-Obesity Drugs: Mechanisms of Action
    • 2.7.1. Lipase Inhibitors
    • 2.7.2. Anorectic Drugs
    • 2.7.3. Off-Label Use of Drugs in Obesity Treatment
    • 2.7.4. Need for Developments and Innovation in the Treatment of Obesity
    • 2.7.5. Unmet Needs and Market Potential

3. The World Anti-Obesity Treatments Market, 2011-2021

  • 3.1. Anti-Obesity Drug Sales from 2009 Onwards: Market Overview
  • 3.2. Leading Companies and their Products
  • 3.3. Current Challenges with Anti-Obesity Drugs
    • 3.3.1. Difficulties with Xenical, Alli and Reductil
    • 3.3.2. Challenges with Acomplia
    • 3.3.3. Challenges with Phentermine
  • 3.4. Overall World Anti-Obesity Market Forecast, 2011-2021
    • 3.4.1. Anti-Obesity Treatments Market Growth, 2011-2021

4. Individual Anti-Obesity Drug Forecasts by Therapeutic Class, 2011-2021

  • 4.1. Lipase Inhibitors
    • 4.1.1. Xenical World Market Forecast 2011-2021
    • 4.1.2. Can Xenical Remain in the Market?
    • 4.1.3. Xenical Sales Down Through Generic Competition
    • 4.1.4. Can Pipeline Drugs Push Xenical out of the Market?
    • 4.1.5. Alli World Market Forecast 2011-2021
    • 4.1.6. Alli a Form of Orlistat: First OTC Variation by GSK
    • 4.1.7. Can Alli Resist Generic Competition?
    • 4.1.8. Alli: Additional Health Benefits?
  • 4.2. Anorectic Drugs
    • 4.2.1. Reductil/Meridia Forecast 2011-2021
    • 4.2.2. EU Decision on Reductil (Early 2010)
    • 4.2.3. US Decision on Reductil (Late 2010)
    • 4.2.4. Reductil Out of the Market
    • 4.2.5. Reductil' s Absence Creating a Hole in the Market
    • 4.2.6. World Dinintel Market Forecast 2011-2021
  • 4.3. Phentermine
    • 4.3.1. World Duromine Market Forecast 2011-2021
    • 4.3.2. Duromine Sales During the Forecast Period
  • 4.4. Other Anti-Obesity Drugs: World Market Forecast 2011-2021
    • 4.4.1. Generic Competitors
    • 4.4.2. New Drug: Contrave (Orexigen)
    • 4.4.3. New Drug: Lorcaserin (Arena)
    • 4.4.4. New Drug: Qnexa (Vivus)
    • 4.4.5. New Drug: Liraglutide (Novo Nordisk)
    • 4.4.6. New Drug: Empatic/Excalia (Orexigen)
  • 4.5. Market Summary
    • 4.5.1. New Drugs Will Refresh the Obesity Market
    • 4.5.2. Market Opportunities Through Innovation
    • 4.5.3. The Challenges with Anorectic Drugs
    • 4.5.4. The Challenges with Lipase Inhibitors
    • 4.5.5. The Future of Anti-Obesity Treatments

5. Drivers and Restraints in the World Anti-Obesity Treatments Market, 2011-2021

  • 5.1. Strengths
    • 5.1.1. Long-Term Therapy with Anti-Obesity Drugs
    • 5.1.2. Prospects of Multiple Indications for Anti-Obesity Drugs
    • 5.1.3. Growing Demand for New Drugs in this Market
    • 5.1.4. Off-Label Potential in Some Markets
    • 5.1.5. Strong Development Pipeline
  • 5.2. Weaknesses
    • 5.2.1. Limited Efficacy Observed in Prominent Drugs
    • 5.2.2. Undesirable Side-Effects
    • 5.2.3. Increased Competition from New Drugs and Generic Substitutes
    • 5.2.4. Strict Regulatory Hurdles: Companies Pay the Price
    • 5.2.5. Pharmacotherapy Not Likely to Become the First Line of Treatment
  • 5.3. Opportunities
    • 5.3.1. Rising Prevalence of Obesity Gives a Large Potential Market for Drugs
    • 5.3.2. Increasing Potential for Success in Emerging Economies: India and China
    • 5.3.3. Medical and Cosmetic Use of Anti-Obesity Drugs
    • 5.3.4. High Governmental Awareness of the Obesity Problem Stimulates the Market
    • 5.3.5. Pipeline Drugs Can Eventually Stimulate the Market
    • 5.3.6. Diet and Exercise May be the Mainstay Treatment, but this Approach to Weight Management is Not Always Effective
    • 5.3.7. Potential Shift from Rx (Prescription Only) to OTC (Over-the-Counter) Products
  • 5.4. Threats
    • 5.4.1. Lack of Reimbursement May Continue to be a Limiting Factor
    • 5.4.2. Threats from Other Treatment Forms and Alternative Medicine
    • 5.4.3. Regulatory Threats: Drug Recalls Decrease Confidence in Treatments, Harming the Overall Market
    • 5.4.4. Shift to Healthier Lifestyles and Awareness Programmes Threaten the Anti-Obesity Drug Market?
    • 5.4.5. Long-Term Safety Issues Continue to Inhibit Market Growth
    • 5.4.6. Opinion of Prescribers, the Media and the Public Affects Product Success and the Success of the Overall Market
  • 5.5. Summary of Chapter

6. R&D Pipeline for Anti-Obesity Treatments

  • 6.1. Treatments Currently in Phase III
    • 6.1.1. Contrave (Orexigen): FDA Approves Contrave
    • 6.1.2. Cetilistat (Alizyme/Takeda)
    • 6.1.3. Liraglutide (Novo Nordisk)
    • 6.1.4. Canagliflozin (Johnson & Johnson)
  • 6.2. Treatments Currently in Phase II
    • 6.2.1. Empatic/Excalia (Orexigen)
    • 6.2.2. Obinepitide (7TM Pharma)
    • 6.2.3. Davalintide (Amylin/Takeda)
    • 6.2.4. BMS 830216 (Bristol-Myers Squibb)
    • 6.2.5. Velneperit (Shionogi)
    • 6.2.6. Sodium Tungstate (Bayer/Barcelona University)
    • 6.2.7. Serglifozin Etabonate (GlaxoSmithKline/Kissei)
    • 6.2.8. Pramlintide and Metreleptin (Amylin)
    • 6.2.9. Hoodia Gordonii Extract (Phytopharm/Council for Scientific and Industrial Research)
    • 6.2.10. MTP Inhibitor (Johnson & Johnson)
    • 6.2.11. TM 30339 (7TM Pharma)
    • 6.2.12. KRP 204 (Kyorin)
  • 6.3. Treatments Currently in Phase I
    • 6.3.1. Trodusquemine (Genaera)
    • 6.3.2. THCV (GW Pharmaceuticals)
    • 6.3.3. Oral PYY3-36 (Emisphere)
    • 6.3.4. AZD 4017 (AstraZeneca)
    • 6.3.5. AZD 6714 (AstraZeneca)
    • 6.3.6. AZD 1656 (AstraZeneca)
    • 6.3.7. NGD 4715 (Neurogen)
    • 6.3.8. OAP 189 (Pfizer)
    • 6.3.9. PF 4325667 (Pfizer)
    • 6.3.10. SRT 2104 (Sirtris/GlaxoSmithKline)
    • 6.3.11. ZYO 1 (Zydus Calida)
    • 6.3.12. BVT 74316 (Biovitrum)
    • 6.3.13. CP 404 (Compellis/Louisiana State University)
    • 6.3.14. TTP 435 (TransTech)
    • 6.3.15. PRX 07034 (Epix)
    • 6.3.16. PSN 602 (OSI Pharmaceuticals)
    • 6.3.17. TKS 1225 (Wyeth/Pfizer)
  • 6.4. Promising Pipeline Possibilities
    • 6.4.1. Melanotan
    • 6.4.2. Increasing Mitochondrial Activity to Increase Energy Expenditure
    • 6.4.3. Inhibiting the Creation of Fat Stores after Gut Absorption
    • 6.4.4. Anti-Obesity Vaccine in the Pipeline
    • 6.4.5. Vitamin B12 Injections

7. Anti-Obesity Drugs: Leading National Markets 2011-2021

  • 7.1. The Overall Market for Anti-Obesity Drug Treatments
  • 7.2. Drug Development Will Drive the Market
  • 7.3. The US Anti-Obesity Treatments Market 2011-2021
    • 7.3.1. Patent Expiries, FDA Warnings and New Drug Releases will Create a Turbulent Market
    • 7.3.2. Market Growth in the Second Half of the Forecast Period
  • 7.4. UK Anti-Obesity Market Forecast 2011-2021
    • 7.4.1. Lagging Sales and Reductil' s European Withdrawal
    • 7.4.2. Government Policy Will Benefit the Anti-Obesity Treatments Market in the UK
  • 7.5. Spanish Anti-Obesity Market Forecast 2011-2021
    • 7.5.1. New Drug Releases, Reductil' s European Withdrawal and Patent Expiries Will Affect Short Term Growth
    • 7.5.2. The Market Will Show Consistent Positive Growth from 2012 Onwards
  • 7.6. German Anti-Obesity Market Forecast 2011-2021
  • 7.7. French Anti-Obesity Market Forecast 2011-2021
    • 7.7.1. Reimbursement Will Drive Steady Sales Growth Throughout the Forecast Period
  • 7.8. Italian Anti-Obesity Treatments Market 2011-2021
  • 7.9. Japanese Anti-Obesity Treatments Market 2011-2021
  • 7.10. Russian Anti-Obesity Treatments Market 2011-2021
  • 7.11. Top 5 EU Markets 2011-2021
  • 7.12. Emerging Markets: Indian Anti-Obesity Treatments Market 2011-2021
  • 7.13. Emerging Markets: Chinese Anti-Obesity Treatments Market 2011-2021
  • 7.14. Other Countries: Anti-Obesity Market Forecast 2011-2021
    • 7.14.1. Revenues from the Other Countries Group Will Grow Significantly Throughout the Forecast Period
    • 7.14.2. The Impact of Emerging Markets Will Contribute Heavily to Total Other Countries Market Growth

8. Expert Opinions from Our Survey

  • 8.1. Interview with an Obesity Treatment Professional in Spain
    • 8.1.1. Views on the Efficacy of Drugs for Obesity Treatment
    • 8.1.2. Potential Obesity Treatments in the R&D Pipeline
    • 8.1.3. Views on Major Anti-Obesity Drugs
    • 8.1.4. Other Ways to Tackle the Obesity Problem: Diet, Exercise and Surgery
    • 8.1.5. Insight into the Spanish Anti-Obesity Treatments Market
    • 8.1.6. Drivers and Restraints in the Market
    • 8.1.7. Future of the Anti-Obesity Treatments Market
  • 8.2 .Interview with Dr Marcio Mancini, Secretary of Endocrinology, Faculty of Medicine, University of Sao Paulo, Brazil
    • 8.2.1. Views on the Anti-Obesity Treatments Market
    • 8.2.2. R&D Pipeline for Anti-Obesity Treatments
    • 8.2.3. Scope for Pharmacotherapy in the Treatment of Obesity
    • 8.2.4. Drivers and Restraints in the Market

9. Conclusions

  • 9.1. Obesity is a Chronic Disorder with Serious Effects on Health
  • 9.2. The Anti-Obesity Market will Expand from 2011 to 2021
  • 9.3. Main Drivers and Restraints in the Anti-Obesity Drug Market
  • 9.4. Geographical Overview of the Anti-Obesity Market
  • 9.5. Outlook for the Future

List of Tables

  • Table 2.1: BMI Classification Bands
  • Table 2.2: Costs Incurred by the NHS (UK) for Anti-Obesity Treatments, 1999-2008 Table 2.3 Obesity Prevalence Among US Adults, 1991-2009
  • Table 3.1: Revenues ($m) for Leading Companies in the Anti-Obesity Drug Market, 2009
  • Table 3.2: Revenues ($m) for Leading Anti-Obesity Drug Treatments, 2009-2015
  • Table 3.3: Revenues ($m) for Leading Anti-Obesity Drug Treatments, 2015-2021
  • Table 3.4: Market Shares (%) of Leading Companies, 2009 and 2010
  • Table 3.5: World Anti-Obesity Drug Treatment Revenues ($m), 2009-2015
  • Table 3.6: World Anti-Obesity Drug Treatment Revenues ($m), 2015-2021
  • Table 4.1: World Xenical Revenues ($m), 2009-2015
  • Table 4.2: World Xenical Revenues ($m), 2015-2021
  • Table 4.3: World Alli Revenues ($m), 2009-2015
  • Table 4.4: World Alli Revenues ($m), 2015-2021
  • Table 4.5: World Reductil Revenues ($m), 2009-2015
  • Table 4.6: World Reductil Revenues ($m), 2015-2021
  • Table 4.7: World Dinintel Revenues ($m), 2009-2015
  • Table 4.8: World Dinintel Revenues ($m), 2015-2021
  • Table 4.9: World Duromine Revenues ($m), 2009-2015
  • Table 4.10: World Duromine Revenues ($m), 2015-2021
  • Table 4.11: Other Anti-Obesity Drug Treatments: World Revenues ($m), 2009-2015
  • Table 4.12: Other Anti-Obesity Drug Treatments: World Revenues ($m), 2015-2021
  • Table 4.13: Anti-Obesity Drugs: World Market Shares (%) and Revenues ($m), 2015 and 2021
  • Table 5.1: SWOT Analysis of the Anti-Obesity Drug Treatments Market, 2011-2021
  • Table 6.1: Drugs Recently Rejected by the FDA
  • Table 6.2: R&D Pipeline for Anti-Obesity Drug Treatments, 2010
  • Table 7.1: Leading National Market Revenues ($m) for Anti-Obesity Drug Treatments, 2009-2015
  • Table 7.2: Leading National Market Revenues ($m) for Anti-Obesity Drug Treatments, 2015-2021
  • Table 7.3: US Anti-Obesity Drug Market Revenues ($m), 2009-2015
  • Table 7.4: US Anti-Obesity Drug Market Revenues ($m), 2015-2021
  • Table 7.5: UK Anti-Obesity Drug Market Revenues ($m), 2009-2015
  • Table 7.6: UK Anti-Obesity Drug Market Revenues ($m), 2015-2021
  • Table 7.7: Spanish Anti-Obesity Drug Market Revenues ($m), 2009-2015
  • Table 7.8: Spanish Anti-Obesity Drug Market Revenues ($m), 2015-2021
  • Table 7.9: German Anti-Obesity Drug Market Revenues ($m), 2009-2015
  • Table 7.10: German Anti-Obesity Drug Market Revenues ($m), 2015-2021
  • Table 7.11: French Anti-Obesity Drug Market Revenues ($m), 2009-2015
  • Table 7.12: French Anti-Obesity Drug Market Revenues ($m), 2015-2021
  • Table 7.13: Italian Anti-Obesity Drug Market Revenues ($m), 2009-2015
  • Table 7.14: Italian Anti-Obesity Drug Market Revenues ($m), 2015-2021
  • Table 7.15: Russian Anti-Obesity Drug Market Revenues ($m), 2009-2015
  • Table 7.16: Russian Anti-Obesity Drug Market Revenues ($m), 2015-2021
  • Table 7.17: Top 5 EU Countries: Revenues ($m) for Anti-Obesity Drug Treatments, 2009-2015
  • Table 7.18: Top 5 EU Countries: Revenues ($m) for Anti-Obesity Drug Treatments, 2015-2021
  • Table 7.19: Indian Anti-Obesity Drug Market Revenues ($m), 2009-2015
  • Table 7.20: Indian Anti-Obesity Drug Market Revenues ($m), 2015-2021
  • Table 7.21: Rest of the World: Anti-Obesity Drug Market Revenues ($m), 2009-2015
  • Table 7.22: Rest of the World: Anti-Obesity Drug Market Revenues ($m), 2015-2021
  • Table 7.23: World Market Shares (%) for Anti-Obesity Drug Treatments, 2009-2021

List of Figures

  • Figure 2.1: Obesity Prevalence among US Adults, 1991-2009
  • Figure 3.1: Revenues ($m) for Leading Companies in the Anti-Obesity Drug Treatments Market, 2009
  • Figure 3.2: World Market Shares (%) of Leading Anti-Obesity Drugs, 2009
  • Figure 3.3: Market Shares (%) of Leading Industry Players, 2009
  • Figure 3.4: Market Shares (%) of Leading Industry Players, 2010
  • Figure 3.5: Total Anti-Obesity Drug Treatments Market: Revenues ($m), 2009-2021
  • Figure 4.1: World Xenical Revenues ($m), 2009-2021
  • Figure 4.2: World Alli Revenues ($m), 2009-2021
  • Figure 4.3: World Reductil Revenues ($m), 2009-2021
  • Figure 4.4: World Dinintel Revenues ($m), 2009-2021
  • Figure 4.5: World Duromine Revenues ($m), 2009-2021
  • Figure 4.6: Total Other Anti-Obesity Drugs: World Revenues ($m), 2009-2021
  • Figure 4.7: Top Tier Anti-Obesity Drug Revenues ($m), 2011-2021
  • Figure 4.8: World Revenues ($m) of Market Leaders in the Anti-Obesity Drug Treatments Market, 2009-2021
  • Figure 4.9: World Market Shares (%) of Leading Anti-Obesity Drugs, 2015
  • Figure 4.10: World Market Shares (%) of Leading Anti-Obesity Drugs, 2021
  • Figure 7.1: US Anti-Obesity Drug Market Revenues ($m), 2009-2021
  • Figure 7.2: UK Anti-Obesity Drug Market Revenues ($m), 2009-2021
  • Figure 7.3: Spanish Anti-Obesity Drug Market Revenues ($m), 2009-2021
  • Figure 7.4: German Anti-Obesity Drug Market Revenues ($m), 2009-2021
  • Figure 7.5: French Anti-Obesity Drug Market Revenues ($m), 2009-2021
  • Figure 7.6: Italian Anti-Obesity Drug Market Revenues ($m), 2009-2021
  • Figure 7.7: Russian Anti-Obesity Drug Market Revenues ($m), 2009-2021
  • Figure 7.8: Top 5 EU Countries: Revenues ($m) for Anti-Obesity Drug Treatments, 2011-2021
  • Figure 7.9: Indian Anti-Obesity Drug Market Revenues ($m), 2009-2021
  • Figure 7.10: Rest of the World Anti-Obesity Drug Market Revenues ($m), 2009-2021
  • Figure 7.11: World Market Shares (%) for Anti-Obesity Drug Treatments, 2009
  • Figure 7.12: World Market Shares (%) for Anti-Obesity Drug Treatments, 2015
  • Figure 7.13: World Market Shares (%) for Anti-Obesity Drug Treatments, 2021
  • Figure 7.14: Anti-Obesity Drug Treatments: Geographical Market Revenues ($m), 2009-2021

Companies Listed

  • 7TM Pharma
  • Abbott Laboratories
  • Ache Laboratories
  • Actavis
  • Alizyme
  • American Home Products
  • American Obesity Association
  • Amylin
  • Arena Pharmaceuticals
  • AstraZeneca
  • Athersys
  • Barcelona University
  • Bayer
  • Bayer Schering
  • Biovitrum
  • Braasch Biotech LLC
  • Bristol-Myers Squibb
  • Clinuvel
  • Compellis
  • Council for Scientific and Industrial Research
  • Duke University
  • Eli Lilly
  • European Medicines Agency (EMEA/EMA)
  • Emisphere
  • EMS
  • Epix
  • Eurofarma
  • Food and Drug Administration (US FDA)
  • Forbes Medi-Tech
  • Gate Pharmaceuticals
  • Genaera
  • GlaxoSmithKline
  • Graceway Pharma
  • GW Pharmaceuticals
  • Han Wha
  • Hanmi
  • Inova Pharma
  • International Association for the Study of Obesity
  • Johnson & Johnson
  • Kalypsys
  • Kissei
  • KVK-Tech
  • Kyorin
  • Liomont
  • Louisiana State University
  • Medley
  • Menarini
  • Merck & Co.
  • National Health Service (NHS)
  • Neurogen
  • NeuroSearch
  • Nintendo
  • Nisshin Pharma
  • Nisshin Seifun Group
  • North American Association for the Study of Obesity
  • Novartis
  • Novo Nordisk
  • Nycomed Pharma
  • OBEcure
  • Orexigen
  • Organisation for Economic Cooperation and Development (OECD)
  • OSI Pharmaceuticals
  • Pennington Biomedical Research Institute, Louisiana State University
  • Pfizer
  • Phytopharm
  • Public Citizen
  • Rimsa Mexico
  • Roche
  • Sanofi-Aventis
  • Shionogi
  • Sirtris Pharmaceuticals
  • Solvay
  • Surface Logix
  • Taisho
  • Takeda Pharmaceutical Company
  • Teva
  • Transition
  • TransTech
  • University of Alberta
  • URL Pharma
  • US Department of Health and Human Services
  • Vernalis
  • Vivus
  • World Health Organization (WHO)
  • Wyeth (now part of Pfizer)
  • Zydus Cadila
Back to Top